Sympathetic activation and endothelial dysfunction in polycystic ovary syndrome are not explained by either obesity or insulin resistance

Clinical Endocrinology

Volumn 83, Issue 6, 2015, Pages 812-819

  Lambert, Elisabeth A ^a,b   Teede, Helena ^b   Sari, Carolina Ika ^a   Jona, Eveline ^b   Shorakae, Soulmaz ^b   Woodington, Kiri ^a   Hemmes, Robyn ^a   Eikelis, Nina ^a   Straznicky, Nora E ^a   De Courten, Barbora ^b   Dixon, John B ^a   Schlaich, Markus P ^a,c   Lambert, Gavin W ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADRENERGIC SYSTEM; ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; FIRING RATE; HEART RATE VARIABILITY; HUMAN; HUMAN CELL; HYPEREMIA; INCIDENCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MUSCLE CONTRACTION; MUSCLE SYMPATHETIC NERVE ACTIVITY; NERVE CELL; NEUROGRAPHY; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; SPIKE; VASCULAR EQUIPMENT; BLOOD; CARDIOVASCULAR DISEASE; HEART RATE; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYCYSTIC OVARY SYNDROME; RISK FACTOR;

ADULT; CARDIOVASCULAR DISEASES; FEMALE; HEART RATE; HUMANS; INSULIN RESISTANCE; OBESITY; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; SYMPATHETIC NERVOUS SYSTEM;

EID: 84929448421     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12803     Document Type: Article

References (36)

1. Boyle, J.A., Cunningham, J., O'Dea, K., et al,. (2012) Prevalence of polycystic ovary syndrome in a sample of Indigenous women in Darwin, Australia. Medical Journal of Australia, 196, 62-66.
2. Lim, S.S., Davies, M.J., Norman, R.J., et al,. (2012) Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update, 18, 618-637.
3. Barry, J.A., Kuczmierczyk, A.R., &, Hardiman, P.J., (2011) Anxiety and depression in polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction, 26, 2442-2451.
4. Joham, A.E., Ranasinha, S., Zoungas, S., et al,. (2014) Gestational diabetes and type 2 diabetes in reproductive-aged women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 99, E447-E452.
5. Hillman, J.K., Johnson, L.N., Limaye, M., et al,. (2014) Black women with polycystic ovary syndrome (PCOS) have increased risk for metabolic syndrome and cardiovascular disease compared with white women with PCOS [corrected]. Fertility and Sterility, 101, 530-535.
6. Sverrisdottir, Y.B., Mogren, T., Kataoka, J., et al,. (2008) Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth? American Journal of Physiology. Endocrinology and Metabolism, 294, E576-E581.
7. Stener-Victorin, E., Jedel, E., Janson, P.O., et al,. (2009) Low-frequency electroacupuncture and physical exercise decrease high muscle sympathetic nerve activity in polycystic ovary syndrome. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 297, R387-R395.
8. Schlaich, M.P., Straznicky, N., Grima, M., et al,. (2011) Renal denervation: a potential new treatment modality for polycystic ovary syndrome? Journal of Hypertension, 29, 991-996.
9. Lambert, E., Sari, C.I., Dawood, T., et al,. (2010) Sympathetic nervous system activity is associated with obesity-induced subclinical organ damage in young adults. Hypertension, 56, 351-358.
10. Carmina, E., Orio, F., Palomba, S., et al,. (2006) Endothelial dysfunction in PCOS: role of obesity and adipose hormones. American Journal of Medicine, 119 (356), e351-e356.
11. Lambert, E., Dawood, T., Straznicky, N., et al,. (2010) Association between the sympathetic firing pattern and anxiety level in patients with the metabolic syndrome and elevated blood pressure. Journal of Hypertension, 28, 543-550.
12. Alvarez, G.E., Beske, S.D., Ballard, T.P., et al,. (2002) Sympathetic neural activation in visceral obesity. Circulation, 106, 2533-2536.
13. Esler, M., Straznicky, N., Eikelis, N., et al,. (2006) Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension, 48, 787-796.
14. Rotterdam, E.A.-S.P.C.W.G., (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility, 81, 19-25.
15. Spielberger, C., (1988) State-trait Anger Expression Inventory: Professional Manual. Psychological Assessment Resources, Odessa.
16. Tooke, J.E., (1995) Microvascular function in human diabetes. A physiological perspective. Diabetes, 44, 721-726.
17. Yucel, A., Noyan, V., &, Sagsoz, N., (2006) The association of serum androgens and insulin resistance with fat distribution in polycystic ovary syndrome. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 126, 81-86.
18. Straznicky, N.E., Lambert, E.A., Lambert, G.W., et al,. (2005) Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. Journal of Clinical Endocrinology and Metabolism, 90, 5998-6005.
19. Lambert, E., Hering, D., Schlaich, M., et al,. (2012) Advances in sympathetic nerve recording in humans. Frontiers in Physiology, 3, 11.
20. Davies, S.J., &, Allgulander, C., (2013) Anxiety and cardiovascular disease. Modern Trends in Pharmacopsychiatry, 29, 85-97.
21. Jedel, E., Gustafson, D., Waern, M., et al,. (2011) Sex steroids, insulin sensitivity and sympathetic nerve activity in relation to affective symptoms in women with polycystic ovary syndrome. Psychoneuroendocrinology, 36, 1470-1479.
22. Saranya, K., Pal, G.K., Habeebullah, S., et al,. (2014) Assessment of cardiovascular autonomic function in patients with polycystic ovary syndrome. The Journal of Obstetrics and Gynaecology Research, 40, 192-199.
23. Martelli, D., Silvani, A., McAllen, R.M., et al,. (2014) The low frequency power of heart rate variability is neither a measure of cardiac sympathetic tone nor of baroreflex sensitivity. American Journal of Physiology. Heart and Circulatory Physiology, 307, H1005-H1012.
24. Kahal, H., Aburima, A., Ungvari, T., et al,. (2013) Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity. Clinical Endocrinology, 79, 252-258.
25. Carmina, E., (2013) Obesity, adipokines and metabolic syndrome in polycystic ovary syndrome. Frontiers of Hormone Research, 40, 40-50.
26. Tarkun, I., Arslan, B.C., Canturk, Z., et al,. (2004) Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. Journal of Clinical Endocrinology and Metabolism, 89, 5592-5596.
27. Virdis, A., Neves, M.F., Duranti, E., et al,. (2013) Microvascular endothelial dysfunction in obesity and hypertension. Current Pharmaceutical Design, 19, 2382-2389.
28. Schlaich, M.P., Kaye, D.M., Lambert, E., et al,. (2003) Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation, 108, 560-565.
29. Lambert, E.A., Rice, T., Eikelis, N., et al,. (2014) Sympathetic activity and markers of cardiovascular risk in nondiabetic severely obese patients: the effect of the initial 10% weight loss. American Journal of Hypertension, 27, 1308-1315.
30. Viazzi, F., Leoncini, G., Adami, G.F., et al,. (2011) Sub-clinical organ damage in hypertension and obesity. Nutrition, Metabolism and Cardiovascular Diseases, 21, 597-602.
31. Palomba, S., Falbo, A., Zullo, F., et al,. (2009) Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocrine Reviews, 30, 1-50.
32. Gudbjornsdottir, S., Friberg, P., Elam, M., et al,. (1994) The effect of metformin and insulin on sympathetic nerve activity, norepinephrine spillover and blood pressure in obese, insulin resistant, normoglycemic, hypertensive men. Blood Pressure, 3, 394-403.
33. Pelletier, L., &, Baillargeon, J.P., (2010) Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice. Fertility and Sterility, 94, 2665-2669.
34. Wenzel, R.R., Spieker, L., Qui, S., et al,. (1998) I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives. Hypertension, 32, 1022-1027.
35. Chazova, I., Almazov, V.A., &, Shlyakhto, E., (2006) Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Diabetes, Obesity & Metabolism, 8, 456-465.
36. Topal, E., Cikim, A.S., Cikim, K., et al,. (2006) The effect of moxonidine on endothelial dysfunction in metabolic syndrome. American Journal of Cardiovascular Drugs, 6, 343-348.